Jeil Pharma Holdings Valuation

Q: What is the Fair Price of A002620 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A002620 (₩8480) is trading above our estimate of [[fair value]] (₩7482.22)

Is A002620 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A002620 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A002620 (₩8480) is trading above our estimate of fair value (₩7482.22)

Significantly Below Fair Value: A002620 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A002620?

Key metric: As A002620 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A002620. This is calculated by dividing A002620's market cap by their current revenue.
What is A002620's PS Ratio?
PS Ratio	0.2x
Sales	₩778.79b
Market Cap	₩129.10b

A002620 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.4x
Enterprise Value/EBITDA	-1409.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A002620's PS Ratio compare to its peers?

The above table shows the PS ratio for A002620 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.1x
A063160 CKD Bio	0.8x	n/a	₩124.8b
A002720 Kukje Pharma	0.7x	n/a	₩115.7b
A106190 High Tech Pharm	1.9x	n/a	₩152.1b
A011040 Kyung Dong Pharmaceutical	0.9x	n/a	₩164.9b
A002620 Jeil Pharma Holdings	0.2x	n/a	₩129.1b

Price-To-Sales vs Peers: A002620 is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (1.1x).

Price to Sales Ratio vs Industry

How does A002620's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	0.8x	13.6%
A002620 Jeil Pharma Holdings	0.2x	n/a	US$92.44m
A009290 Kwang Dong Pharmaceutical	0.1x	n/a	US$160.13m
A096760 JW Holdings	0.2x	n/a	US$151.97m

5 Companies		Estimated Growth	Market Cap
Industry Avg.	0.8x	31.7%
A002620 Jeil Pharma Holdings	0.2x	n/a	US$92.44m

No more companies

Price-To-Sales vs Industry: A002620 is good value based on its Price-To-Sales Ratio (0.2x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A002620's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A002620 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A002620's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

JW Pharmaceutical

₩591.4b

Manufactures and sells medicines and medical supplies in Japan and internationally.

A001060

₩23,650.00

-2.3%

-17.5%

Hugel

₩2.8t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩259,000.00

-5.3%

67.2%

J2KBIO

₩54.3b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,510.00

2.7%

n/a